gradient centrifugation. (C) Cells for culture were then enriched with MACS technology using two strategies achievable with currently available reagents for the Miltenyi "CliniMACS" system. (D) PBMCs were enriched in a two-step selection involving CD8 + depletion, followed by CD25 + enrichment. (D') Alternatively, PBMCs were positively selected for CD4 + , then stained for CD4, CD25, CD127 and CD45RA, (D'') followed by sorting on a BD FACSAria II into CD4 + CD25 hi CD127 lo CD45RA + and CD4 + CD25 hi CD127 lo CD45RA -subsets. (E) Each enriched population was stimulated with anti-CD3/anti-CD28 coated Dynabeads and cultured for 20-24 days in X-VIVO15 supplemented with 5% human AB serum, IL-2 and rapamycin. ILX2 was replenished every other day. Cells were re-stimulated and placed in fresh medium at day 12. (D) Poor viability at 5 days meant that assessment of proliferation was not feasible.
